SOMAVERT is the first in a new class of medicines called growth hormone receptor antagonists
and the only medicine designed to specifically block the effects of excess growth hormone in acromegaly.
Food and Drug Administration (FDA) for Somavert (pegvisomant), a growth hormone receptor antagonist
for the treatment of acromegaly.
Shearwater") today announced a license agreement with Sensus Drug Development Corporation ("Sensus") for the PEGylation of Sensus' Somavert(TM) (pegvisomant for injection) human growth hormone receptor antagonist
using Shearwater's proprietary technology.
Sensus Drug Development Corporation today announced the positive results of its pivotal Phase III clinical trial with its lead compound, pegvisomant (B2036-PEG), a novel growth hormone receptor antagonist
Sensus is in late Phase III development of pegvisomant (B2036-PEG), a growth hormone receptor antagonist
for the treatment of a rare condition called acromegaly, also known as "gigantism.